Clinical Trial Update: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of CD30-directed CAR T cells for relapsed CD30-expressing Hodgkin lymphoma and non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD30 CAR T cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkin's Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING